Study guide
6.3 Genitourinary Syndrome of Menopause (GSM) & Postmenopausal Osteoporosis
WHNP-BC Women's Health Nurse Practitioner Study Guide Exam
Track your progress as you read
Finished sections get a check mark.
1 Introduction: About the WHNP-BC Exam
WHNP-BC Exam Facts, Blueprint & Study Plan
2 Chapter 1: Well-Woman Care, Assessment & Gynecologic Screening
1.1 Well-Woman Health Maintenance & Routine Screening Across the Lifespan 1.2 Comprehensive Health History & Physical Examination (Female and Male) 1.3 Cervical Cancer Screening & ASCCP Risk-Based Management Guidelines 1.4 Breast Health Assessment, Diagnostic Imaging & Breast Cancer Screening
3 Chapter 2: Vulvovaginal Infections, STIs & HIV Prevention
2.1 Vulvovaginitis: Bacterial Vaginosis, Candidiasis & Trichomoniasis 2.2 Sexually Transmitted Infections: Chlamydia, Gonorrhea, Syphilis & Pelvic Inflammatory Disease 2.3 Viral STIs & Chronic Vulvar Dermatoses (HSV, HPV, Lichen Sclerosus & Lichen Planus) 2.4 HIV Prevention (PrEP & PEP), Viral Hepatitis, Mycoplasma genitalium & Ectoparasites
4 Chapter 3: Gynecologic Disorders, Pelvic Pain & Gynecologic Cancers
3.1 Abnormal Uterine Bleeding & the FIGO PALM-COEIN Classification 3.2 Uterine Leiomyomas, Adenomyosis & Endometrial and Cervical Polyps 3.3 Dysmenorrhea, Endometriosis & Chronic Pelvic Pain Management 3.4 Benign Pelvic Masses, Pelvic Organ Prolapse & Urinary Incontinence 3.5 Gynecologic Malignancies: Endometrial, Ovarian, Cervical, Vulvar & Vaginal Cancers
5 Chapter 4: Reproductive Physiology, Endocrinology & Infertility
4.1 Reproductive Anatomy, Puberty, the Menstrual Cycle & Müllerian Anomalies 4.2 Polycystic Ovary Syndrome (PCOS) & Hyperandrogenic Disorders 4.3 Amenorrhea Evaluation: Primary & Secondary Etiologies 4.4 Infertility Workup, Ovulation Induction & Assisted Reproductive Technologies
6 Chapter 5: Contraception, Family Planning & Unintended Pregnancy
5.1 Long-Acting Reversible Contraception (LARC): IUDs & Subdermal Implants 5.2 Hormonal Contraceptives: Combined & Progestin-Only Methods 5.3 Emergency Contraception, Barrier Methods & Fertility Awareness-Based Methods 5.4 CDC U.S. Medical Eligibility Criteria (US MEC) & Permanent Sterilization 5.5 Unintended Pregnancy: Options Counseling, Medication & Procedural Abortion
7 Chapter 6: Perimenopause, Menopause & Postmenopausal Health
6.1 Menopausal Transition Physiology, Vasomotor Symptoms & Clinical Staging (STRAW+10) 6.2 Menopausal Hormone Therapy (MHT): Indications, Regimens & Contraindications 6.3 Genitourinary Syndrome of Menopause (GSM) & Postmenopausal Osteoporosis
8 Chapter 7: Sexual Health, Male Reproductive Health & LGBTQ+ Care
7.1 Female Sexual Function, Sexual Dysfunction & LGBTQ+ Sexual Health 7.2 Male Sexual & Reproductive Health: STIs, Infertility, Contraception & Sexual Dysfunction
9 Chapter 8: Preconception, Fetal Development & Normal Antepartum Care
8.1 Preconception Counseling, Risk Assessment & Teratogen Exposure 8.2 Early Pregnancy Diagnosis, Gestational Dating & Initial Prenatal Evaluation 8.3 Embryonic & Fetal Development, the Placenta, Fetal Circulation & Amniotic Fluid 8.4 Routine Antepartum Surveillance, Nutritional Needs & Weight Gain Guidelines 8.5 Management of Common Discomforts & Physiologic Changes in Pregnancy
10 Chapter 9: Antepartum Complications I: Hypertension, Diabetes, Bleeding & Preterm Birth
9.1 Hypertensive Disorders of Pregnancy & Preeclampsia Management 9.2 Gestational Diabetes Mellitus: Screening, Glycemic Targets & Management 9.3 Bleeding in Pregnancy: Spontaneous Abortion, Ectopic Pregnancy & Placental Disorders 9.4 Preterm Labor, PPROM & Cervical Insufficiency
11 Chapter 10: Antepartum Complications II: Infections, Medical Disorders & Fetal Conditions
10.1 Infections in Pregnancy: CMV, Parvovirus, Varicella, Rubella, Toxoplasmosis, Listeria, GBS & HIV 10.2 Maternal Medical Disorders in Pregnancy: Pregestational Diabetes, Epilepsy, Thrombocytopenia, Obesity & Cardiac Disease 10.3 Gestational Trophoblastic Disease, Recurrent Loss, Stillbirth & Perinatal Bereavement 10.4 Multiple Gestation, Fetal Growth Disorders, Amniotic Fluid Abnormalities, Malpresentation & Postterm Pregnancy 10.5 Rh(D) Alloimmunization & Hemolytic Disease of the Fetus and Newborn
12 Chapter 11: Intrapartum Principles & Fetal Surveillance
11.1 Electronic Fetal Monitoring (EFM): Baseline, Variability, Decelerations & Categories 11.2 Labor Assessment, Stages of Labor & Labor Dystocia 11.3 Trial of Labor After Cesarean (TOLAC) & Intrapartum Emergencies
13 Chapter 12: Postpartum Management, Lactation & Puerperal Complications
12.1 Postpartum Involution, Physical Recovery & Routine Puerperal Care 12.2 Postpartum Hemorrhage: The 4 Ts, Uterotonic Pharmacotherapy & Emergency Protocols 12.3 Puerperal Infections & Postpartum Mood Disorders 12.4 Physiology of Lactation, Common Breastfeeding Challenges & Infant Feeding 12.5 Other Puerperal Complications: Hematomas, Urinary Retention, Hemorrhoids, Postpartum Hypertension & Warning Signs
14 Chapter 13: Primary Care: Cardiovascular, Thromboembolic, Respiratory & HEENT Conditions
13.1 Hypertension & Cardiovascular Disease in Women: Gender-Specific Presentations 13.2 Dyslipidemia & ASCVD Risk: The 2026 ACC/AHA Guideline 13.3 Venous Thromboembolism in Women: Risk, Diagnosis, Treatment & Prevention in Pregnancy 13.4 Respiratory Conditions in Women: Asthma Management & Respiratory Infections 13.5 HEENT & Upper Respiratory Conditions: Conjunctivitis, Rhinitis, Pharyngitis, Sinusitis, Otitis & the Common Cold
15 Chapter 14: Primary Care: Endocrine, Metabolic & Gastrointestinal Disorders
14.1 Type 2 Diabetes Mellitus & Metabolic Syndrome in Women 14.2 Obesity, Weight Management & Healthy Lifestyle Counseling 14.3 Thyroid Disorders: Hypothyroidism, Hyperthyroidism & Postpartum Thyroiditis 14.4 Gastrointestinal Conditions: GERD, Irritable Bowel Syndrome & Gallbladder Disease 14.5 Constipation, Hemorrhoids, Peptic Ulcer Disease & Other Upper and Lower GI Disorders
16 Chapter 15: Primary Care: Renal, Hematologic, Rheumatologic, Musculoskeletal & Dermatologic Health
15.1 Urinary Tract Infections, Pyelonephritis, Hematuria & Nephrolithiasis 15.2 Anemias in Women: Iron Deficiency, Microcytic & Macrocytic Anemias 15.3 Autoimmune & Rheumatologic Conditions: SLE, Antiphospholipid Syndrome, RA & Fibromyalgia 15.4 Musculoskeletal Complaints: Low Back Pain, Osteoarthritis, Sprains, Strains & Common Conditions in Women 15.5 Common Dermatologic Disorders in Women Across the Lifespan 15.6 Common Skin Conditions: Eczema, Contact Dermatitis, Psoriasis, Tinea, Vitiligo, Skin Lesions & Hidradenitis
17 Chapter 16: Neurologic, Mental Health, Behavioral & Psychosocial Care
16.1 Headache Disorders in Women: Migraine, Tension-Type, Red Flags & Hormonal Considerations 16.2 Depressive Disorders & Anxiety in Women Across the Reproductive Lifespan 16.3 Substance Use Disorders: Alcohol, Nicotine, Cannabis & Opioid Use in Women 16.4 Intimate Partner Violence (IPV), Sexual Assault & Trauma-Informed Care
18 Chapter 17: Assessment, Diagnostic Testing & Interpretation
17.1 Laboratory Diagnostics: Hematology, Coagulation, Chemistry, Hormone, Serologic & Screening Tests 17.2 Genetic Principles: Inheritance Patterns, Carrier Screening & Hereditary Cancer Risk Assessment 17.3 Gynecologic Office Diagnostic Procedures: Wet Mounts, Endometrial Biopsy & Colposcopy 17.4 Obstetric Diagnostic Imaging & Genetic Screening Modalities
19 Chapter 18: Pharmacology: Pharmacokinetics, Pharmacodynamics, Pharmacogenetics & Safe Prescribing
18.1 Clinical Pharmacokinetics Across the Female Lifespan & the FDA PLLR 18.2 Pharmacodynamics, Pharmacogenetics & Clinically Important Drug Interactions in Women's Health 18.3 Antimicrobial Stewardship & Pharmacotherapy in Pregnancy and Lactation
20 Chapter 19: Professional Role, Legal, Ethical, Quality & Health Equity Responsibilities
19.1 APRN Scope of Practice, Consensus Model & Collaborative Practice 19.2 Legal, Ethical & Informed Consent Issues in Reproductive Health Care 19.3 Evidence-Based Practice, Research Terminology, Quality Improvement & Patient Safety 19.4 Maternal Health Equity, Cultural Humility & Gender-Affirming Gynecologic Care
6.3 Genitourinary Syndrome of Menopause (GSM) & Postmenopausal Osteoporosis
Key Takeaways Explain This Topic AI
Genitourinary Syndrome of Menopause (GSM) results from estrogen deficiency causing thinning of the vulvovaginal epithelium, loss of rugae, cellular glycogen depletion, loss of protective Lactobacillus species, and vaginal pH elevation (>5.0).
First-line pharmacotherapy for symptomatic GSM refractory to non-hormonal moisturizers and lubricants is low-dose local vaginal estrogen; systemic absorption is minimal and does NOT require opposing progestogen even in women with an intact uterus.
Routine osteoporosis screening with central Dual-Energy X-ray Absorptiometry (DEXA) is universally recommended for all women aged 65 and older, and for postmenopausal women under 65 at increased risk on a formal clinical risk assessment (USPSTF 2025).
Osteoporosis is diagnosed by a DEXA T-score of <= -2.5 at the lumbar spine, femoral neck, or total hip, or by the clinical occurrence of a low-trauma fragility fracture regardless of bone mineral density.
First-line pharmacologic treatment for osteoporosis consists of oral bisphosphonates (alendronate, risedronate), which require strict administration on an empty stomach with plain water remaining upright for 30 minutes; denosumab requires prompt transition to a bisphosphonate upon cessation to prevent rebound vertebral fractures.
Last updated: October 2026
Genitourinary Syndrome of Menopause (GSM): Pathophysiology
Genitourinary Syndrome of Menopause (GSM) is a progressive hypoestrogenic condition affecting the vulva, vagina, urethra, and bladder. Unlike vasomotor symptoms, GSM does not improve spontaneously and affects up to 50% to 70% of postmenopausal women.
Estrogen Depletion & Vaginal Dysbiosis
The lower urogenital tract shares an embryological origin from the urogenital sinus and has a high concentration of estrogen receptors (ER-alpha and ER-beta). Hypoestrogenism triggers distinct microenvironmental changes:
Epithelial Atrophy: Stratified squamous epithelium thins from 30–40 layers to 3–5 layers of basal/parabasal cells. Submucosal capillary networks regress and collagen hyalinizes, causing loss of vaginal rugae, mucosal pallor, decreased distensibility, and introital stenosis.
Glycogen Depletion: Thinning epithelium depletes cellular glycogen, the primary metabolic substrate for commensal Lactobacillus species.
pH Elevation & Dysbiosis: Diminished Lactobacillus colonization impairs lactic acid production, causing vaginal pH to rise from an acidic 3.8–4.5 to an alkaline pH >5.0 (frequently 6.0–7.5) .
Loss of Colonization Resistance: Elevated pH allows proliferation of enteric pathogens ( Escherichia coli , Klebsiella , Enterococcus ), predisposing to dyspareunia, secondary vaginitis, and recurrent postmenopausal urinary tract infections (UTIs).
- Clinical Spectrum & Stepwise Management of GSM
- Clinical Presentation
Vulvovaginal: Vaginal dryness, burning, pruritus, dyspareunia, introital tearing, postcoital bleeding, mucosal petechiae, labial resorption, and clitoral phimosis.
Urinary: Dysuria, urgency, frequency, nocturia, and recurrent UTIs (≥2 culture-proven UTIs in 6 months or ≥3 in 12 months).
Stepwise Management Ladder
Tier Agent Regimen Clinical Practice Pearls
Tier 1: Non-Hormonal Vaginal Moisturizers & Lubricants • Moisturizers: Polycarbophil or hyaluronic acid 2–3 times weekly. • Lubricants: Water- or silicone-based applied prior to coitus. First-line for mild symptoms or hormonal contraindications; improves hydration without reversing underlying tissue atrophy.
Tier 2: First-Line Pharmacotherapy Low-Dose Local Vaginal Estrogens • Estradiol tablet (10 mcg): Daily x 2 weeks, then twice weekly. • Estradiol cream 0.01% (0.5 g): Daily x 1–2 weeks, then twice weekly. • Estradiol ring (Estring 2 mg): Replaced every 90 days. Restores rugae, glycogen, and lactobacilli; lowers pH and cuts recurrent UTIs by >50%. Systemic absorption is negligible (<10–20 pg/mL); opposing progestogen is NOT required , even with an intact uterus.
Tier 3: Alternative Therapies Intravaginal Prasterone & Oral Ospemifene • Prasterone (DHEA 6.5 mg ovule): Daily at bedtime. • Ospemifene (60 mg tablet): Daily with food. • Prasterone: Local intracellular conversion to estrogens/androgens without raising serum steroids. • Ospemifene: Oral SERM approved for moderate-to-severe dyspareunia.
Note
In breast cancer survivors with refractory GSM, low-dose local vaginal estrogens or prasterone may be considered after shared decision-making and written oncologic clearance, as systemic absorption rarely exceeds postmenopausal baseline levels.
Postmenopausal Osteoporosis: Bone Remodeling Pathophysiology
Bone remodeling balances osteoclast resorption with osteoblast matrix synthesis:
Estrogen promotes osteoclast apoptosis and stimulates osteoprotegerin (OPG) production by osteoblasts. OPG acts as a decoy receptor binding RANKL (Receptor Activator of Nuclear Factor Kappa-B Ligand) , preventing it from activating its receptor ( RANK ) on osteoclasts.
Postmenopausal estrogen loss removes this brake: OPG levels fall, and RANKL activity surges, driving unchecked osteoclastogenesis and prolonging osteoclast lifespan.
This uncoupling accelerates bone loss at rates of 1% to 5% per year during the first 5 to 7 years post-menopause , predisposing to fragility fractures of the vertebrae, femoral neck, and distal radius (Colles fracture).
Screening Guidelines & DEXA Diagnostic Criteria
The goal of screening is preventing low-trauma fragility fractures (fractures occurring from a fall from standing height or less).
Screening Guidelines
Universal Screening: Central Dual-Energy X-ray Absorptiometry (DEXA) of the femoral neck and lumbar spine is indicated for all women aged 65 and older .
Targeted Screening (<65 Years): Indicated for postmenopausal women under 65 with major fracture risk factors: BMI <20 kg/m², current smoking, parental hip fracture, chronic glucocorticoids (≥5 mg prednisone daily for ≥3 months), rheumatoid arthritis, or increased risk on a validated tool such as FRAX or OST (the 2025 USPSTF statement names no single FRAX cutoff).
T-Score Diagnostic Classifications (Central DEXA)
BMD is reported as a T-score , comparing patient bone mineral density to healthy young adult reference norms:
Classification DEXA T-Score Threshold Clinical Significance
Normal T-score ≥ -1.0 Normal bone density within 1 SD of reference mean.
Osteopenia (Low Bone Mass) T-score between -1.0 and -2.5 Mild-to-moderate loss; calculate FRAX to determine treatment eligibility.
Osteoporosis T-score ≤ -2.5 Marked loss at lumbar spine, femoral neck, or total hip.
Clinical Osteoporosis Low-trauma fragility fracture Diagnosed clinically regardless of T-score (even if osteopenic or normal).
Tip
A Z-score ≤ -2.0 (compared to age-matched norms) indicates secondary osteoporosis, warranting evaluation for hyperparathyroidism, celiac disease, multiple myeloma, or severe vitamin D deficiency.
- Comprehensive Osteoporosis Management & Pharmacotherapy
- Non-Pharmacologic Foundations
Elemental Calcium: 1,200 mg daily (dietary preferred). If supplements are used, calcium carbonate requires gastric acid (take with meals); calcium citrate is absorbed acid-independently and is preferred with PPI therapy or achlorhydria.
Vitamin D3: 800 to 1,000 IU daily (target serum 25-hydroxyvitamin D ≥30 ng/mL).
Lifestyle: Progressive weight-bearing/resistance exercise, smoking cessation, and home fall prevention.
Pharmacologic Treatment Indications
Treatment is indicated for:
T-score ≤ -2.5 at femoral neck, total hip, or lumbar spine.
Low-trauma hip or vertebral fragility fracture regardless of T-score.
Osteopenia with FRAX 10-year risk of major osteoporotic fracture ≥20% or hip fracture ≥3% .
- Pharmacologic Classes
- 1. First-Line Antiresorptive: Oral Bisphosphonates
Agents: Alendronate (70 mg weekly) or risedronate (35 mg weekly).
Administration Rules: Oral bioavailability is <1% and blocked by food. Patients must take the drug first thing in the morning with 8 oz plain water, remain upright for ≥30 minutes, and defer all food/medications for ≥30 minutes to prevent chemical esophagitis.
Rare Risks: Atypical femoral fractures (AFF) and osteonecrosis of the jaw (ONJ).
Drug Holiday: Consider a holiday after 3 to 5 years of oral therapy (or 3 years of IV zoledronic acid 5 mg annual infusion) in low-to-moderate risk patients.
2. RANKL Inhibitor: Denosumab (Prolia)
Dosing: 60 mg subcutaneous injection every 6 months.
Critical Warning (Rebound Fractures): Denosumab does not bind bone matrix. Discontinuation triggers rapid bone turnover rebound and severe multiple vertebral fractures . Denosumab must NEVER be stopped without immediately transitioning to an alternative bisphosphonate .
3. Anabolic Agents (Bone Builders)
Teriparatide (PTH 1-34) & Abaloparatide (PTHrP): Daily subcutaneous injections for up to 2 years for severe osteoporosis (T-score ≤ -3.0 or prior fracture); must be followed by an antiresorptive agent.
Romosozumab: Sclerostin antibody stimulating bone formation while suppressing resorption; monthly subcutaneous injections for 12 months.